A Bondoc, H M Golbar, M Pervin, C Katou-Ichikawa, M Tanaka, T Izawa, M Kuwamura, J Yamate
{"title":"肿瘤相关髓系细胞参与F344大鼠无色素黑色素瘤(RMM肿瘤系)的进展,特别是MHC II类和cd163表达细胞","authors":"A Bondoc, H M Golbar, M Pervin, C Katou-Ichikawa, M Tanaka, T Izawa, M Kuwamura, J Yamate","doi":"10.1007/s12307-017-0193-x","DOIUrl":null,"url":null,"abstract":"<p><p>Tumor progression is often influenced by infiltration of myeloid cells; depending on the M1- or M2-like activation status, these cells may have either inhibitory or promoting effects on tumor growth. We investigated the properties of tumor-associated myeloid cells in a previously established homotransplantable amelanotic melanoma (RMM tumor line) in F344 rats. RMM tumor nodules were allowed to reach the sizes of 0.5, 1, 2 and 3 cm, respectively. Immunohistochemistry and flow cytometry was performed for macrophage markers CD68 and CD163, and for the antigen-presenting cell marker, MHC class II. Although no significant change was observed in the number of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages during RMM progression, the number of MHC class II<sup>+</sup> antigen-presenting cells was reduced in 3 cm nodules. Real-time RT-PCR of laser microdissection samples obtained from RMM regions rich in MHC class II<sup>+</sup> cells demonstrated high expressions of M1-like factors: IFN-γ, GM-CSF and IL-12a. Furthermore, fluorescence-activated cell sorting, followed by real-time RT-PCR for CD11b<sup>+</sup> MHC class II<sup>+</sup> (myeloid antigen-presenting cells), CD11b<sup>+</sup> CD163<sup>+</sup> (M2 type myeloid cells), CD11b<sup>+</sup> CD80<sup>+</sup> (M1 type myeloid cells) and CD11b<sup>+</sup> CD11c<sup>+</sup> (dendritic cells) cells was performed. Based on the levels of inflammation- and tumor progression-related factors, MHC class II<sup>+</sup> antigen-presenting cells showed polarization towards M1, while CD163<sup>+</sup> macrophages, towards M2. CD80<sup>+</sup> and CD11c<sup>+</sup> myeloid cells did not show clear functional polarization. Our results provide novel information on tumor-associated myeloid cells in amelanotic melanoma, and may become useful in further research on melanoma immunity.</p>","PeriodicalId":9425,"journal":{"name":"Cancer Microenvironment","volume":"10 1-3","pages":"9-24"},"PeriodicalIF":0.0000,"publicationDate":"2017-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s12307-017-0193-x","citationCount":"5","resultStr":"{\"title\":\"Participation of Tumor-Associated Myeloid Cells in Progression of Amelanotic Melanoma (RMM Tumor Line) in F344 Rats, with Particular Reference to MHC Class II- and CD163-Expressing Cells.\",\"authors\":\"A Bondoc, H M Golbar, M Pervin, C Katou-Ichikawa, M Tanaka, T Izawa, M Kuwamura, J Yamate\",\"doi\":\"10.1007/s12307-017-0193-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Tumor progression is often influenced by infiltration of myeloid cells; depending on the M1- or M2-like activation status, these cells may have either inhibitory or promoting effects on tumor growth. We investigated the properties of tumor-associated myeloid cells in a previously established homotransplantable amelanotic melanoma (RMM tumor line) in F344 rats. RMM tumor nodules were allowed to reach the sizes of 0.5, 1, 2 and 3 cm, respectively. Immunohistochemistry and flow cytometry was performed for macrophage markers CD68 and CD163, and for the antigen-presenting cell marker, MHC class II. Although no significant change was observed in the number of CD68<sup>+</sup> and CD163<sup>+</sup> macrophages during RMM progression, the number of MHC class II<sup>+</sup> antigen-presenting cells was reduced in 3 cm nodules. Real-time RT-PCR of laser microdissection samples obtained from RMM regions rich in MHC class II<sup>+</sup> cells demonstrated high expressions of M1-like factors: IFN-γ, GM-CSF and IL-12a. Furthermore, fluorescence-activated cell sorting, followed by real-time RT-PCR for CD11b<sup>+</sup> MHC class II<sup>+</sup> (myeloid antigen-presenting cells), CD11b<sup>+</sup> CD163<sup>+</sup> (M2 type myeloid cells), CD11b<sup>+</sup> CD80<sup>+</sup> (M1 type myeloid cells) and CD11b<sup>+</sup> CD11c<sup>+</sup> (dendritic cells) cells was performed. Based on the levels of inflammation- and tumor progression-related factors, MHC class II<sup>+</sup> antigen-presenting cells showed polarization towards M1, while CD163<sup>+</sup> macrophages, towards M2. CD80<sup>+</sup> and CD11c<sup>+</sup> myeloid cells did not show clear functional polarization. Our results provide novel information on tumor-associated myeloid cells in amelanotic melanoma, and may become useful in further research on melanoma immunity.</p>\",\"PeriodicalId\":9425,\"journal\":{\"name\":\"Cancer Microenvironment\",\"volume\":\"10 1-3\",\"pages\":\"9-24\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2017-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s12307-017-0193-x\",\"citationCount\":\"5\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Cancer Microenvironment\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s12307-017-0193-x\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2017/6/16 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Microenvironment","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s12307-017-0193-x","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2017/6/16 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Participation of Tumor-Associated Myeloid Cells in Progression of Amelanotic Melanoma (RMM Tumor Line) in F344 Rats, with Particular Reference to MHC Class II- and CD163-Expressing Cells.
Tumor progression is often influenced by infiltration of myeloid cells; depending on the M1- or M2-like activation status, these cells may have either inhibitory or promoting effects on tumor growth. We investigated the properties of tumor-associated myeloid cells in a previously established homotransplantable amelanotic melanoma (RMM tumor line) in F344 rats. RMM tumor nodules were allowed to reach the sizes of 0.5, 1, 2 and 3 cm, respectively. Immunohistochemistry and flow cytometry was performed for macrophage markers CD68 and CD163, and for the antigen-presenting cell marker, MHC class II. Although no significant change was observed in the number of CD68+ and CD163+ macrophages during RMM progression, the number of MHC class II+ antigen-presenting cells was reduced in 3 cm nodules. Real-time RT-PCR of laser microdissection samples obtained from RMM regions rich in MHC class II+ cells demonstrated high expressions of M1-like factors: IFN-γ, GM-CSF and IL-12a. Furthermore, fluorescence-activated cell sorting, followed by real-time RT-PCR for CD11b+ MHC class II+ (myeloid antigen-presenting cells), CD11b+ CD163+ (M2 type myeloid cells), CD11b+ CD80+ (M1 type myeloid cells) and CD11b+ CD11c+ (dendritic cells) cells was performed. Based on the levels of inflammation- and tumor progression-related factors, MHC class II+ antigen-presenting cells showed polarization towards M1, while CD163+ macrophages, towards M2. CD80+ and CD11c+ myeloid cells did not show clear functional polarization. Our results provide novel information on tumor-associated myeloid cells in amelanotic melanoma, and may become useful in further research on melanoma immunity.
期刊介绍:
Cancer Microenvironment is the official journal of the International Cancer Microenvironment Society (ICMS). It publishes original studies in all aspects of basic, clinical and translational research devoted to the study of cancer microenvironment. It also features reports on clinical trials.
Coverage in Cancer Microenvironment includes: regulation of gene expression in the cancer microenvironment; innate and adaptive immunity in the cancer microenvironment, inflammation and cancer; tumor-associated stroma and extracellular matrix, tumor-endothelium interactions (angiogenesis, extravasation), cancer stem cells, the metastatic niche, targeting the tumor microenvironment: preclinical and clinical trials.